Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

The RAS oncogene is both the most frequently mutated oncogene in human cancer and the
first confirmed human oncogene to be discovered in 1982. After decades of research, in …

Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth
factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC) …

Gut microbiota are linked to chronic inflammation and carcinogenesis. Chemotherapy failure
is the major cause of recurrence and poor prognosis in colorectal cancer patients. Here, we …

Objectives: To develop evidence-based guideline recommendations through a systematic
review of the literature to establish standard molecular biomarker testing of colorectal cancer …

Purpose: KRAS mutations occur in approximately 25% of patients with non–small cell lung
cancer (NSCLC). Despite the uniform presence of KRAS mutations, patients with KRAS …

New non-invasive approaches that can complement and improve on current strategies for
colorectal cancer (CRC) screening and management are urgently needed. A growing …

Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver
mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), and …

All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …